Sun Pharma launches ILUMYA medicine to treat Plaque psoriasis in Canada
29th Oct 2021

Sun Pharmaceutical Industries has launched its medicine ILUMYA used in the treatment of adults with moderate-to-severe plaque psoriasis in Canada. ILUMYA (tildrakizumab injection) has already completed a five-year study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis. With five years of effective treatment of moderate-to-severe plaque psoriasis, ILUMYA demonstrates the company‚Äôs commitment to providing innovative medicines to support patient lifestyle and physician choice.

The results showed that patients with moderate-to-severe plaque psoriasis maintained consistent, high levels of skin clearance and a durable safety profile through five years of continuous treatment. In Canada, some patients involved in the study have reported still having clear skin eight years later.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.